P

Inventor

QI CHAO

US22 patents
⚠️ This page may combine multiple inventors who share the name “QI CHAO”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

INCYTE CORP

16 patents
US11339149B2May 24, 2022

Heterocyclic compounds as immunomodulators

INCYTE CORP24 citations94
US10800768B2Oct 13, 2020

Heterocyclic compounds as immunomodulators

INCYTE CORP30 citations94
US11607416B2Mar 21, 2023

Bicyclic heterocycles as FGFR inhibitors

INCYTE CORP7 citations85
US11161850B2Nov 2, 2021

Fused pyrazine derivatives as A2A / A2B inhibitors

INCYTE CORP5 citations84
US11673894B2Jun 13, 2023

Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors

INCYTE CORP4 citations74
US12441731B2Oct 14, 2025

Pyrazolopyrimidine compounds and uses thereof

INCYTE CORP0 citations62
US12083124B2Sep 10, 2024

Bicyclic heterocycles as FGFR inhibitors

INCYTE CORP1 citations62
US11111247B2Sep 7, 2021

Pyrazolopyrimidine compounds and uses thereof

INCYTE CORP1 citations62
US11939328B2Mar 26, 2024

Quinoline compounds as inhibitors of KRAS

INCYTE CORP0 citations61
US11999740B2Jun 4, 2024

Fused pyrazine derivatives as A2A / A2B inhibitors

INCYTE CORP0 citations59
US12378243B2Aug 5, 2025

Quinoline compounds as inhibitors of KRAS

INCYTE CORP0 citations56
US12077539B2Sep 3, 2024

Imidazole and triazole KRAS inhibitors

INCYTE CORP0 citations52
US11591329B2Feb 28, 2023

Bicyclic heterocycles as FGFR inhibitors

INCYTE CORP0 citations52
US12466822B2Nov 11, 2025

Heterocyclic compounds as immunomodulators

INCYTE CORP0 citations51
US12060433B2Aug 13, 2024

CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy

INCYTE CORP0 citations49
US12441742B2Oct 14, 2025

Naphthyridine compounds as inhibitors of KRAS

INCYTE CORP0 citations47

TENCENT TECH SHENZHEN CO LTD

3 patents

NANJING UNIVERSITY OF TECHNOLOGY

1 patent

GAONA AERO MAT CO LTD

1 patent

QI CHAO

1 patent